Sirima, Sodiomon B <br/><br/>
Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children.  [electronic resource] 

 -  PloS one  Oct 2009 
 - e7549 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1932-6203 
<br/><br/><label>Standard No.: </label>10.1371/journal.pone.0007549  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antigens, Protozoan--genetics<br/>Burkina Faso<br/>Child, Preschool<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Humans<br/>Infant<br/>Malaria--prevention & control<br/>Malaria Vaccines--therapeutic use<br/>Merozoites--immunology<br/>Peptides--chemistry<br/>Plasmodium falciparum--metabolism<br/>Protozoan Proteins--genetics<br/>Research Design<br/>Time Factors<br/>Treatment Outcome